Pipeline & Platform


PT010 is a triple-drug combination of the long-acting muscarinic antagonist (LAMA) glycopyrronium, the long acting β2-agonist (LABA) formoterol fumarate and budesonide, an inhaled corticosteroid (ICS). As with Pearl’s monotherapy and dual therapy Co-SuspensionTM delivery technology product candidates, PT010 is delivered via a standard MDI.

PT008 / PT009

PT008 is Pearl's monotherapy Co-SuspensionTM Delivery Technology candidate containing budesonide, an inhaled corticosteroid (ICS). PT009 is the dual combination of the long acting β2-agonist (LABA) formoterol fumarate and budesonide. By leveraging the flexibility of Pearl’s Co-SuspensionTM Delivery Technology platform, the Company has been able to formulate these mono and dual candidates, as well as the PT010 triple combination with virtually no coformulation effects.